New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to ...

A gospel truth in ophthalmology has been that people of African ancestry are more likely to develop glaucoma, but a new study clouded the picture. The long-term cohort study has identified modifiable ...

Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the ...

The US Food and Drug Administration (FDA) has approved aprocitentan (Tryvio) to lower blood pressure, in combination with other antihypertensive agents, in adults with treatment-resistant hypertension ...

The FDA has approved aprocitentan (Tryvio), making it the first endothelin receptor antagonist for the treatment of high blood pressure (BP), Idorsia Pharmaceuticals announced on Wednesday. The ...

AI-powered retinal imaging closes healthcare gaps, enables earlier intervention, and reveals new insights into systemic ...

Dear Dr. Roach: I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a cardiologist and learned that I had mild to moderate mitral stenosis ...